 |
Vol.49 No.6 contents | Japanese/English |
 | Full Text of PDF (264K) Article in Japanese |
- The 23rd Lung Cancer Workshop -
Clinical Medicine of Molecular Targeted Drugs -New Molecular Targeted Drugs for Lung Cancer-
Nobuyuki Yamamoto1, Takehito Shukuya11Thoracic Oncology Division, Shizuoka Cancer Center, Japan
Several clinical trials have shown that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective for EGFR mutation-positive advanced lung cancer, and a phase III study to prove survival benefit is ongoing. EGFR antibody and irreversible EGFR-TKIs are representative EGFR-targeted agents, but not reversible EGFR-TKI. Concerning EGFR antibodies, studies to evaluate cetuximab, matuzumab and nimotuzumab are ongoing. A phase III study of chemotherapy with or without cetuximab has shown promising results in EGFR-positive non-small cell lung cancer (NSCLC) patients. Concerning irreversible EGFR-TKIs, phase II and III studies of HKI-272, BIBW-2992, PF-299804 are being conducted for second line or more advanced treatment of NSCLC. We hope that development of these drugs will be effective in the treatment of lung cancer.
key words: Non-small cell lung cancer, Molecular targeted drugs, Epidermal growth factor receptor antibody, Epidermal growth factor receptor-tyrosine kinase inhibitor, Irreversible epidermal growth factor receptor-tyrosine kinase inhibitor
JJLC 49 (6): 957-961, 2009
